Magnetic hydrogel with long in situ retention time for self-regulating temperature hyperthermia. (1st January 2021)

• Record Type: Journal Article
• Authors: Ding, Shuai-Wen; Wu, Cheng-Wei; Yu, Xiao-Gang; Li, Heng; Yu, Li; Zhang, Yu-Xiang; Yang, Ren-Peng; Zhang, Wei
• Is Part Of: International journal of hyperthermia. Volume 38:Number 1(2021)
• Page Start: 13
• Page End: 21
• Publication Date: 2021-01-01
• Subjects: Magnetic hydrogel -- magnetic nanoparticles -- hyperthermia -- self-regulating temperature; biocompatibility; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2020.1863479
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Aim: Magnetic hydrogels (MHGs) have been proposed to avoid the redistribution and loss of magnetic nanoparticles (MNPs) when administrated by intratumoral injection. However, the requirement of complex cooling systems and temperature monitoring systems still hinder the clinical application of MHGs. This study investigates the feasibility of developing an MHG to realize the self-regulation of hyperthermia temperature. Methods: The MHG was developed by dispersing the MNPs with self-regulating temperature property into the temperature-sensitive hydrogel through physical crosslinking. The MHG's gelation temperature was tested by measuring the storage modulus and loss modulus on a rotational rheometer. The biocompatibility of the MHG and MNPs was characterized by CCK-8 assay against HaCaT cells. The in vivo magnetic heating property was examined through monitoring the temperature in the MHG on mice back upon the application of the alternating magnetic field (400 ± 5 Oe, 100 ± 5 kHz) every week for successive six weeks. Results: The gelation temperature of the MHG falls in 28.4°C-37.4°C. At in vivo applied concentration of 80 mg/mL, the MHG exhibits over 80% cell viability after 72 h, significantly higher than 50% cell viability of the MNPs ( p <0.001). The MHG's stable magnetic hyperthermia temperatures in vivo are in the range of 43.4°C–43.8°C. Conclusions: The developed MHG can be injected using a syringe and will solidify upon body temperature. The biocompatibility is improved after the MNPs being made into MHG. The MHG can self-regulate the temperature for six weeks, exhibiting application potential for self-regulating temperature hyperthermia.